Free Diabetes CME and Free Endocrinology CME 2017‑2018 | CMEList.com

 


Cardiovascular Disease, Diabetes, and Diabetes Treatments: Understanding the Interrelationships
Free Cardiology CME Free Diiabetes CME Live online March 1, 2017, (Sessions 1 and 2), and March 29, 2017 (Session 3), and available on demand through September 29 2017.
Posted by...Bernard Sklar, MD.
Free Cardiovascular and Diabetes CME Credit hours...3.0.
CME Credits Awarded by....University of Cincinnati.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for primary care clinicians, diabetes specialists, cardiologists, as well as other health care providers who provide front-line glycemic management for type 2 diabetes (T2DM) and its comorbidities.
Educational material updated...March 29, 2017.
Expiration of CME credit...September 29 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, and Novo Nordisk Inc.
This activity consists of three sessions, each of which should take approximately 1 hour to complete.
At the conclusion of Cardiovascular Disease, Diabetes, and Diabetes Treatments, you will be able to:
• Discuss the etiologic and pathophysiologic interconnections among the components of the cardiometabolic syndrome and the development of cardiovascular disease
• Identify pharmacological actions of antidiabetes medications that could potentially impact cardiovascular outcomes
• Describe the rationale for studying the cardiovascular impact of antidiabetes medications
• Compare and contrast antidiabetes pharmacotherapies which can optimize glycemic control and minimize adverse effects on cardiovascular risk and/or disease
• Discuss the efficacy and safety data for recent trials that examined the cardiovascular impact of antidiabetes medications
• Delineate critical assessments of recent cardiovascular outcomes trials for antidiabetes medications with regard to their evidence-based clinical implications

Basal Insulin as a Foundation of Diabetes Treatments: Innovative Approaches Free Diabetes CME
Live online February 1, 2017and April 5, 2017  and available on demand through October 5, 2017.
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...2.0. (1,0 hour for each)
CME Credits Awarded by....Primary Care Network.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for endocrinologists, primary care clinicians, physician assistants, nurse practitioners, pharmacists, certified diabetes educators and other health care providers who provide frontline glycemic management for type 2 diabetes and related conditions.
Educational material updated....April 5, 2017.
Expiration of CME credit...October 5, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
After viewing the two presentations of Basal Insulin as a Foundation of Diabetes Treatments,  you will be better able to:
• Describe the pharmacokinetics and pharmacodynamics of the newer ultra-long basal and follow-on biologic ("biosimilar") insulin formulations and how these differ from older formulations
• Determine indications and methods to transition from analog basal insulin to ultra-long basal insulins and follow-on biologic ("biosimilar") basal insulins to help achieve individualized patient treatment goals
• Examine the evidence-based, guideline-driven protocols for therapeutic advancement to basal insulin therapy alone or in combination with other treatment modalities to achieve individualized patient goals
• Identify potential patient, provider, and health care system barriers to initiation and titration of established and newer basal insulins, and methods to overcome these barriers

Hyperkalemia: Causes, Consequences, and Treatment
Free Hyperkalemia CME Posted by...Bernard Sklar, MD.
Free CME Credit Hours...0.75.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Nephrologists, endocrinologists, cardiologists, internal medicine physicians, primary care physicians and other health care professionals involved in the treatment of patients with hyperkalemia.
Educational material last updated...December 14, 2016.
CME Credit Expires...December 13, 2017.
Financial Support...Relypsa, Inc.
Hyperkalemia: Causes, Consequences, and Treatment consists of three brief video presentations on hyperkalemia.
Upon successful completion of Hyperkalemia: Causes, Consequences, and Treatment, you should be better able to:
• Describe the pathophysiology of hyperkalemia, etiologic factors associated with its presentation, and its potential effect on multiple organ systems.
• Review the symptoms that commonly present in patients with hyperkalemia to assist in determining the appropriate diagnostic follow-up.
Differentiate among the new and emerging agents for hyperkalemia for improved treatment selection.
• Apply the efficacy and safety data of conventional therapy and emerging treatments when selecting therapy for hyperkalemia in patients with chronic kidney disease or end-stage renal disease and chronic heart failure.
• Select the appropriate treatment for patients with diabetes and hyperkalemia.

The Evolution of Basal Insulins: One Step or a Giant Leap? 
Live online October 6, 2016, and available on demand through October 6, 2017.
Posted by...Bernard Sklar, MD.Free Diabetes CME
Free Diabetes CME Credit hours...1.0. 
Also 1 hour ABIM MOC.
CME Credits Awarded by....Primary Care Network
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for primary care clinicians and clinically-focused diabetologists and endocrinologists, diabetes educators, and other non-MD health care professionals involved in the diagnosis, treatment, education, and management of patients with T2DM, as well as other medical practice support staff who interact with people who have diabetes.
Educational material updated... October 6, 2016.
Expiration of CME credit...October 6, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The Evolution of Basal Insulins consists of two lectures:
• Leveraging New Insulin Options to Achieve Goals and Ensure Safety; and
• The Evolution of Basal Insulins: One Small Step or a Giant Leap?
At the conclusion of The Evolution of Basal Insulins, you will be able to:
• Describe how consideration of the pathophysiology of type 2 diabetes, as well as the mechanisms of action of antidiabetes drug classes, can be used to design individualized treatment programs for type 2 diabetes
• Summarize usage parameters for key newer antidiabetes medications, including indications, contraindications, potential adverse effects, and initiation/titration methodology
• Discuss assessment of A1C and glycemic patterns as therapeutic targets, and the monitoring for adverse events as a consideration in the advancement of antidiabetes medication therapies

The Evolving Spectrum of Antidiabetes Medications: Practical Perspectives and Clinical Challenges Free Diabetes CME
Live online October 6, 2016, and available on demand through April 6, 2017.
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...1.0.
CME Credits Awarded by....Primary Care Network
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for primary care clinicians and clinically-focused diabetologists and endocrinologists, diabetes educators, and other non-MD health care professionals involved in the diagnosis, treatment, education, and management of patients with T2DM, as well as other medical practice support staff who interact with people who have diabetes.
Educational material updated... October 6, 2016.
Expiration of CME credit... April 6, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
At the conclusion of The Evolving Spectrum of Antidiabetes Medications, you will be able to:
• Describe how consideration of the pathophysiology of type 2 diabetes, as well as the mechanisms of action of antidiabetes drug classes, can be used to design individualized treatment programs for type 2 diabetes
• Summarize usage parameters for key newer antidiabetes medications, including indications, contraindications, potential adverse effects, and initiation/titration methodology
• Discuss assessment of A1C and glycemic patterns as therapeutic targets, and the monitoring for adverse events as a consideration in the advancement of antidiabetes medication therapies

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis
Posted by...Bernard Sklar, MD. Osteoporosis CME
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Endocrinologists, internal medicine physicians, and other health care professionals involved in the treatment of patients with osteoporosis.
Educational material last updated...September 1, 2016.
CME Credit Expires...August 31, 2017.
Financial Support...Merck & Co., Inc.
Improving Bone Strength and Reducing Fracture Risk in Osteoporosis consists of two brief video lectures on the causes and treatments of osteoporosis.
Upon successful completion of Improving Bone Strength and Reducing Fracture Risk in Osteoporosis, you should be better able to:
• Outline the mechanisms of action of currently available and emerging resorption inhibitors, anabolic agents, and other therapeutic options for osteoporosis.
• Assess screening and diagnostic modalities that allow for the prompt management of osteoporosis.

How Low Can You Go? LDL - Is Lower Really Better?
Posted by...Bernard Sklar, MD. cholesterol CME
Free CME Credit Hours...1.0.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Cardiologists, endocrinologists, primary care physicians, family physicians, internists, and other health care professionals involved in the treatment of patients with dyslipidemia.
Educational material last updated...August 25, 2016.
CME Credit Expires...August 24, 2017.
Financial Support...Amgen.
How Low Can You Go? LDL - Is Lower Really Better?  features interviews with clinical experts, who discuss newly released evidence and guidelines regarding cardiovascular risk assessment, best practices when evaluating patients with elevated LDL-C, clinical study data pertaining to the effects of lowering LDL-C beyond evidence-based recommendations, and use of non-statin therapies for the treatment of dyslipidemia in patients who cannot achieve desired target levels.
Upon successful completion of How Low Can You Go? LDL - Is Lower Really Better?, you should be better able to:
• Incorporate cardiovascular risk assessment, evidence-based guidelines, and best practices when evaluating patients with elevated LDL-C.
• Assess clinical study data pertaining to the effect of lowering LDL-C beyond evidence-based recommendations and its effect on cardiovascular risk reduction.
• Evaluate the use of non-statin therapies for the treatment of dyslipidemia in patients who are intolerant or in patients who cannot achieve desired target levels. • Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.
• Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.

Individualized Management of Patients with T2DM via Combination Therapy: What You Need to Know
Posted by...Bernard Sklar, MD. Free Diabetes CME
Free Diabetes CME Credit Hours...0.50.
Credit is intended primarily for physician assistants .
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Physician Assistants and other health care professionals involved in the management of patients with diabetes.
Educational material last updated...July 19, 2016.
CME Credit Expires...July 18, 2017.
Financial Support...Novo Nordisk, Inc.
Individualized Management of Patients with T2DM via Combination Therapy consists of two interviews:
• Recent Advances in Insulin and Incretin Therapy in Type 2 Diabetes
• Individualizing Treatment with Insulin and Incretin Combination Therapy
Upon successful completion of Individualized Management of Patients with T2DM via Combination Therapy, you should be better able to:
• Implement treatment strategies that reflect recent advances in insulin and incretin-based treatment strategies for the management of T2DM.
• Examine effective strategies to overcome barriers that impede the use of insulin and/or incretin-based therapies for the treatment of T2DM.
• Review recent advances in combination treatment strategies for patients with T2DM and identify patients who may benefit from such regimens.
• Employ safe and effective combination insulin/incretin-based therapy in appropriate patients with T2DM.

The New Insulins are Coming: What Does This Mean to the Practicing Clinician?Free Diabetes CME
Live online June 14, 2016 (Sessions 1 and 2) and August 4, 2016 (Sessions 3 and 4), and available on demand through February 4, 2017
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...1.0.
CME Credits Awarded by....Primary Care Network.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for US-based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes.
Educational material updated...June 14, 2016.
Expiration of CME credit...February 4, 2017.
Financial Support...Novo Nordisk.
At the conclusion of the 4 sessions of The New Insulins are Coming, you will be able to:
Session 1:
• Identify T2DM patients who would benefit from insulin-based therapy
• Discuss strategies to overcome patient and clinician barriers to the successful initiation of insulin therapy
• Differentiate how new and emerging insulin products, including new entities and new modes of administration, differ from previously available insulin products with respect to pharmacokinetic and pharmacodynamic features 
Session 2:
• Apply key, clinically relevant data derived from pivotal trials of new and emerging insulin products
• Identify the potential place in therapy for new insulins, including how these indications compare to those of the previously available insulins
• Explain the similarities and differences between a follow-on (biosimilar) insulin and a reference insulin 
Session 3:
• Delineate methods for initiating and titrating new insulin products
• Explore the potential role for new insulins in helping patients meet diabetes management goals while minimizing adverse effects associated with insulin regimens 
Session 4:
• Apply learnings from previous activities to advance management of your patients using new insulin products
• Develop insulin regimens that are based on the product's pharmacodynamic properties and are tailored to the glycemic control needs of the patient

Diabetes Full Circle: Digesting New Data on Combination Therapy and Cardiovascular Risk Free Diabetes CME
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit Hours...0.75 (Three sections of 0.25 hour each).
American Osteopathic Association (AOA) credit is also provided.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Family physicians, endocrinologists, osteopathic physicians and other health care professionals involved in the treatment of patients with type 2 diabetes mellitus (T2DM).
Educational material last updated...April 19, 2016.
CME Credit Expires...April 18, 2017.
Financial Support...Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
In Diabetes Full Circle, leading experts discuss new guidelines in the management of Type-2 Diabetes Mellitus. The presentation consists of 3 interviews: 
• Digesting New Guidelines: Are They a Game Changer for Treating Diabetes and More?
• Digesting New Data: Combination SGLT2 Inhibitors with DPP-4 Inhibitors
• Digesting New Data in T2DM: Improving CV Risk
After viewing Diabetes Full Circle, you should be better able to:
• Apply newly released evidence and guidelines to practice regarding glycemic management in patients with type 2 diabetes.
• Include new findings about incretin-based therapy and sodium glucose co-transporter 2 inhibitors into management strategies for patients with diabetes.
• Assess the evidence for the use of combined SGLT2/DPP-4 inhibitor therapy to improve glycemic control and other cardiovascular risk factors in patients with type 2 diabetes.

Adult Growth Hormone Deficiency (GHD): Therapeutic Updates, Present Clinical Controversies, and Barriers to Care Free Endocrinology CME
Posted by...Bernard Sklar, MD.
Free Endocrinology CME Credit hours...0.75.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...Healthcare professionals specializing in endocrinology and those who otherwise commonly care for or clinically encounter adult patients with GHD.
Educational material updated...July 12, 2016.
Expiration of CME credit...July 12, 2018.
Financial Support...Novo Nordisk.
After completing Adult Growth Hormone Deficiency (GHD), you will be able to:
• Summarize present guidelines for the diagnosis of GHD
• Describe the underlying pathophysiological and typical clinical features of GHD as they pertain to therapeutic targets.
• Given a patient with GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation.
• Assess and properly manage the significant comorbidities that are associated with GHD and therefore increase mortality in patients with GHD
• Evaluate patient cases during follow-up visits in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence.
In order to get credit from ScientiaCME, you must first establish a username and password.